Trial Profile
Phase I trial of stereotactic body radiotherapy with concurrent pembrolizumab in metastatic urothelial cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 13 Jul 2016 New trial record